Stock Price Quote

VISTA PHARMACEUTICALS LTD.

NSE : NABSE : 524711ISIN CODE : INE427C01021Industry : Pharmaceuticals & DrugsHouse : Private
BSE13.490.44 (+3.37 %)
PREV CLOSE ( ) 13.05
OPEN PRICE ( ) 13.05
BID PRICE (QTY) 12.54 (150)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13289
TODAY'S LOW / HIGH ( )12.50 13.56
52 WK LOW / HIGH ( ) 7.9519.7
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 1991
Management Info
Dhananjaya Alli - Chairman Murali Meraga - Managing Director
Registered Office

Address Plot Nos. 10 To 14 And 16 To 20, T S I I C Industrial Estate,Chityal, Gopalaipalli Village,Narketpally Mandal,
Nalgonda Dist,
Telangana-508254

Phone 08682 272552 / 09291015956

Email admin.hyd@vistapharmaceuticals.com

Website www.vistapharmaceuticals.com

Registrars Details
Aarthi Consultants Pvt Ltd
1-2-285 ,Domalaguda,,Hyderabad
Listing : BSE

NEWS

02Feb Vista Pharmaceuticals informs about bo
Vista Pharmaceuticals has informed that meeting of the Board of Director..
30Dec Vista Pharmaceuticals informs about ou
Vista Pharmaceuticals has informed that pursuant to the special resoluti..
07Sep Vista Pharmaceuticals submits annual r
Vista Pharmaceuticals has informed that it enclosed 32nd Annual Report f..
07Sep Vista Pharmaceuticals informs about AGM
Vista Pharmaceuticals has informed that pursuant to Section 96 of the Co..
07Feb Vista Pharmaceuticals informs about bo
Vista Pharmaceuticals has informed that the meeting of the Board of Dire..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-16.28-58.17
Gross Profit -22 -47.23
Operating Profit -17.2-19.36
Net Sales 17.0410.04

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5450.00 (2.66%)
M.Cap ( in Cr)64785.10
Glaxosmithkline Phar (BSE)
peergroup  2470.00 (3.90%)
M.Cap ( in Cr)41843.29
Gland Pharma (BSE)
peergroup  1879.00 (4.65%)
M.Cap ( in Cr)30778.63
Coral Laboratories (BSE)
peergroup  451.20 (20.00%)
M.Cap ( in Cr)143.98
Pfizer (BSE)
peergroup  4550.00 (1.24%)
M.Cap ( in Cr)21034.81

Shareholding Pattern

NON-INSTITUTION 64.52%
PROMOTERS 35.44%
MUTUAL FUNDS/UTI 0.04%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Vista Pharmaceuticals Ltd.

Vista Pharmaceuticals Ltd. was incorporated in the year 1991. Its today's share price is 13.49. Its current market capitalisation stands at Rs 59.46 Cr. In the latest quarter, company has reported Gross Sales of Rs. 10.04 Cr and Total Income of Rs.14.03 Cr. The company's management includes Barkha Jain, Divakar Reddy Yerrabommanahalli, Umakanth Katta, Divya Bhavani Chakravarthula, Umesh V Banakar, Pavan Sathvik Gilaka, M H Rao, Stanley Prabhakar Reddy, Murali Meraga, Dhananjaya Alli.

It is listed on the BSE with a BSE Code of 524711 , NSE with an NSE Symbol of and ISIN of INE427C01021. It's Registered office is at Plot Nos. 10 To 14 And 16 To 20, T S I I C Industrial Estate,Chityal, Gopalaipalli Village,Narketpally MandalNalgonda Dist-508254, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AM Reddy & DR Reddy, Mahesh Virender & Sriram, PRV Associates, PVR & Associates, V Kishore Kumar & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.